Charged nutritive proteins provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.

Aspects of the disclosure relate to compositions and methods for expressing glycan binding proteins (GBPs) in a cell or cells. In some embodiments, the disclosure provides recombinant Ab-Y3 protein variants and isolated nucleic acids engineered to express the same. In some embodiments, the disclosure provides methods of isolating, purifying, detecting, or screening for certain proteins (e.g., IgG proteins) using recombinant Ab-Y3 protein variants.

Aspects of the disclosure relate to compositions and methods for expressing glycan binding proteins (GBPs) in a cell or cells. In some embodiments, the disclosure provides recombinant Ab-Y3 protein variants and isolated nucleic acids engineered to express the same. In some embodiments, the disclosure provides methods of isolating, purifying, detecting, or screening for certain proteins (e.g., IgG proteins) using recombinant Ab-Y3 protein variants.

Embodiments of the invention are generally directed to lignin-modifying enzymes and systems and methods of their manufacture. In many embodiments, the lignin-modifying enzymes are lignin-degrading enzymes capable of breaking down lignin into component parts that are usable for other purposes. Several embodiments are directed to systems for producing lignin-modifying enzymes in vivo, including in yeast and/or plant species, and certain embodiments are directed to methods of creating these systems, including transfecting the species to produce lignin-modifying enzymes.

Embodiments of the invention are generally directed to lignin-modifying enzymes and systems and methods of their manufacture. In many embodiments, the lignin-modifying enzymes are lignin-degrading enzymes capable of breaking down lignin into component parts that are usable for other purposes. Several embodiments are directed to systems for producing lignin-modifying enzymes in vivo, including in yeast and/or plant species, and certain embodiments are directed to methods of creating these systems, including transfecting the species to produce lignin-modifying enzymes.

The present invention is directed to all aspects of novel methyl transferase enzymes that methylate backbone amides of (poly)peptides. The present invention also relates to nucleic acids encoding these enzymes as well as corresponding vectors and host cells comprising these. Moreover, the present invention encompasses the use of said enzymes for modifying (poly)peptides as well as corresponding methods. Also, the present invention pertains to further novel enzymes for modifying (poly)peptides derived from the omphalotin gene cluster of O. olearius and the homologous gene clusters from D. bispora, L. edodes and F. mediterranea as well as related aspects.

The present invention is directed to all aspects of novel methyl transferase enzymes that methylate backbone amides of (poly)peptides. The present invention also relates to nucleic acids encoding these enzymes as well as corresponding vectors and host cells comprising these. Moreover, the present invention encompasses the use of said enzymes for modifying (poly)peptides as well as corresponding methods. Also, the present invention pertains to further novel enzymes for modifying (poly)peptides derived from the omphalotin gene cluster of O. olearius and the homologous gene clusters from D. bispora, L. edodes and F. mediterranea as well as related aspects.

The compositions and methods are related to plant breeding and methods of identifying and selecting disease resistance genes and plant pathogen effector genes. Provided are methods to identify novel genes that encode plant pathogen effector proteins and proteins providing plant resistance to various diseases and uses thereof. These disease resistant genes are useful in the production of resistant plants through breeding, transgenic modification, or genome editing.

The compositions and methods are related to plant breeding and methods of identifying and selecting disease resistance genes and plant pathogen effector genes. Provided are methods to identify novel genes that encode plant pathogen effector proteins and proteins providing plant resistance to various diseases and uses thereof. These disease resistant genes are useful in the production of resistant plants through breeding, transgenic modification, or genome editing.

The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in reducing damage caused by fine particulate matter on embryos and offspring. Accordingly, the present invention suggests that the Ganoderma immunomodulatory protein administrated to pregnant animals can prevent neurological damages and reduce risk of disorders in embryos and offspring.